Clinical

GLP-1s Before Surgery: Why Anaesthetists Care About Delayed Gastric Emptying

These drugs slow gastric emptying, which is the mechanism that produces satiety. Under anaesthesia it becomes a different problem: a stomach that still holds contents aft

The mechanism, seen from the other side

Slowed gastric emptying is why these drugs work. Food leaves the stomach more slowly, fullness lasts longer, and intake falls. That is the intended effect.

Under general anaesthesia or deep sedation the protective airway reflexes are suppressed. Standard preoperative fasting rules assume a stomach empties on a predictable timetable. If it does not, residual contents can be regurgitated and enter the lungs — pulmonary aspiration, which is uncommon and serious.

The Zepbound prescribing information addresses this directly, noting reports of pulmonary aspiration during general anaesthesia or deep sedation in patients taking tirzepatide, and advising that the delayed gastric emptying be considered before such procedures.

What the label actually says, against what circulates

The label describes a consideration, not a protocol. Holding decisions are made by the anaesthetist and the prescriber together, based on the procedure, the dose, and where the patient is in titration.

Why the guidance is unsettled

Professional societies have issued and revised guidance on preoperative management of GLP-1 receptor agonists, and the recommendations have moved as evidence accumulated. Early advice tended toward simple hold periods; later advice has been more individualised, weighing the aspiration risk against the harm of interrupting treatment for someone with diabetes.

What has not changed is the underlying point: your anaesthetist needs to know you are taking one. That single disclosure is worth more than any hold period a website could quote, because it lets the team choose between delaying the procedure, using a different anaesthetic technique, extending the fast, or assessing gastric contents with ultrasound.

Where this most often goes wrong

The medication is not on the list. People frequently do not think of a weekly weight-loss injection as a medication when a form asks what they take. It belongs on the form.

The programme is separate from the surgical team. A telehealth GLP-1 provider and a hospital rarely share records. Nobody will join those dots unless you do.

The procedure is minor. Sedation for endoscopy, dental work or a scan raises the same question as major surgery.

The preparation is compounded. Then there is no manufacturer label for the anaesthetist to consult, and possibly no clear record of concentration or additives. Bring whatever documentation you have.

What to tell the team, specifically

1. The drug and whether it is a branded or compounded preparation.
2. Your dose in milligrams, and your dosing day.
3. When you last injected, and when the next dose is due.
4. Where you are in titration — recently increased, or steady for months.
5. Whether you currently have nausea, vomiting or a sense of food sitting undigested.

That last one matters more than people expect. Symptoms of delayed emptying at the time of the procedure are more informative than the calendar.

The interruption has its own risk

Holding a GLP-1 is not free. For someone taking it for type 2 diabetes, an interruption affects glycaemic control. For someone on it for weight management, a gap during titration can mean restarting at a lower dose, because tolerability is re-established rather than retained.

That is precisely why the decision belongs with clinicians who can weigh both sides, and why a fixed rule published by a comparison site would be the wrong output. What we can say is that the conversation must happen, and that it frequently does not.

Questions readers actually ask